← Eichor
Study identifier: NCT07515027 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Condition: PONV  ·  Sponsor: Shanghai Chest Hospital

PhaseNA
Planned participants204
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Deputy Chief Physician  ·  +86 18017321631  ·  caixiaoyue2007@163.com

Chief Physician  ·  +86 18017320233  ·  gason2000@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Chest HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07515027